The Methodist Hospital Research Institute: Breast Neoplasms trials

The registry lists 10 Breast Neoplasms studies with The Methodist Hospital Research Institute as lead sponsor. 1 are open to participants now and 8 have results posted.

Phase 1 2Phase 2 9Phase 3 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)RecruitingNCT05660083Phase 2
• Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast CancerActive, not recruitingNCT03820141Phase 2Results posted
• SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLCCompletedNCT03004183Phase 2Results posted
• TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast CancerCompletedNCT02988986Phase 2Results posted
• L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer PatientsCompletedNCT02834403Phase 1/2Results posted
• Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With PaclitaxelCompletedNCT02073487Phase 2Results posted
• Olive Oil for High Risk Breast Cancer Prevention in WomenCompletedNCT02068092Phase 2/3Results posted
• Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)CompletedNCT01446016Phase 2Results posted
• Neo-Adjuvant Study in Triple Negative Breast Cancer PatientsCompletedNCT01097642Phase 2Results posted
• Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast CancerActive, not recruitingNCT03742245Phase 1